Trinity Biotech (FRA:TRB) ROCE % : -30.67% (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Trinity Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Trinity Biotech's annualized ROCE % for the quarter that ended in Sep. 2023 was -30.67%.

Trinity Biotech ROCE % Historical Data

The historical data trend for Trinity Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech ROCE % Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-12.10

-19.31

-0.97

10.86

-35.92

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-36.60	-27.64	-20.01	-88.87	-30.67

Trinity Biotech ROCE % Calculation

Trinity Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-15.599	/	( ( (105.222 - 88.935)	+	(86.946 - 16.368) )	/ 2 )
	=	-15.599	/	( (16.287	+	70.578)	/ 2 )
	=	-15.599	/	43.4325
	=	-35.92 %

Trinity Biotech's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-15.408	/	( ( (66.447 - 13.623)	+	(59.59 - 11.936) )	/ 2 )
	=	-15.408	/	( ( 52.824	+	47.654 )	/ 2 )
	=	-15.408	/	50.239
	=	-30.67 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Trinity Biotech (FRA:TRB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Trinity Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (FRA:TRB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (FRA:TRB) » Definitions » ROCE %

Comparable Companies

STRR CNTG CHEK PMD MYNZ SLDX PRPO XWEL PCHM DMTK TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

TRIB:USA TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.

Trinity Biotech (FRA:TRB) Headlines

No Headlines